Market research
DMN.F Diamyd Medical AB (publ)
F EUR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 11M
- P/E ratio
- Not available
- Analyst target
- 19
- Dividend yield
- Not available
- Beta
- 2.29
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- SE0005162880
- Market cap
- 11M
- P/E ratio
- Not available
- Analyst target
- 19
- Dividend yield
- Not available
- Beta
- 2.29
About
About Diamyd Medical AB (publ)
Diamyd Medical AB (publ) develops precision medicine therapies for the treatment of autoimmune diabetes. The company develops Diamyd, an antigen-specific immunotherapy, which is in phase III clinical trial for the treatment of type 1 diabetes and latent autoimmune diabetes in adults (LADA); and Remygen, an immunomodulation therapy, that is in phase I/II clinical trial for the treatment of with type 1 diabetes, type 2 diabetes, and LADA. It has a research and development collaboration agreement with Juvenile Diabetes Research Foundation to develop DIAGNODE-3 Phase 3 trial in type 1 diabetes. Diamyd Medical AB (publ) was formerly known as Diamyd Therapeutics AB and changed its name to Diamyd Medical AB (publ) in April 2013. The company was founded in 1984 and is headquartered in Stockholm, Sweden.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the DMN.F discussion.
5 years, 5 months ago
Diamyd Medical AB (publ) is currently in a long term uptrend where the price is trading 6.5% above its 200 day moving average.
From a valuation standpoint, the stock is 466.2% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 7437.7.
Diamyd Medical AB (publ)'s total revenue sank by 97.9% to $1K since the same quarter in the previous year.
Its net income has dropped by 59.4% to $15M since the same quarter in the previous year.
Finally, its free cash flow fell by 141.3% to $-15M since the same quarter in the previous year.
Based on the above factors, Diamyd Medical AB (publ) gets an overall score of 1/5.